364 related articles for article (PubMed ID: 19318502)
21. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum.
Ferger B; Leng A; Mura A; Hengerer B; Feldon J
J Neurochem; 2004 May; 89(4):822-33. PubMed ID: 15140182
[TBL] [Abstract][Full Text] [Related]
22. Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.
Oizumi H; Hayashita-Kinoh H; Hayakawa H; Arai H; Furuya T; Ren YR; Yasuda T; Seki T; Mizuno Y; Mochizuki H
Neurosci Res; 2008 Jan; 60(1):15-21. PubMed ID: 17963913
[TBL] [Abstract][Full Text] [Related]
23. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
24. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
25. Identification of brain-derived neurotrophic factor in nestin-expressing astroglial cells in the neostriatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Chen LW; Hu HJ; Liu HL; Yung KK; Chan YS
Neuroscience; 2004; 126(4):941-53. PubMed ID: 15207328
[TBL] [Abstract][Full Text] [Related]
26. FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice.
Zechel S; Jarosik J; Kiprianova I; Schober A; Unsicker K; von Bohlen und Halbach O
Eur J Neurosci; 2006 Mar; 23(6):1671-5. PubMed ID: 16553632
[TBL] [Abstract][Full Text] [Related]
27. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.
Collier TJ; Dung Ling Z; Carvey PM; Fletcher-Turner A; Yurek DM; Sladek JR; Kordower JH
Exp Neurol; 2005 Feb; 191 Suppl 1():S60-7. PubMed ID: 15629762
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
29. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
30. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
31. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
32. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
[TBL] [Abstract][Full Text] [Related]
33. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
34. Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos.
Karen DJ; Li W; Harp PR; Gillette JS; Bloomquist JR
Neurotoxicology; 2001 Dec; 22(6):811-7. PubMed ID: 11829414
[TBL] [Abstract][Full Text] [Related]
35. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
36. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
37. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
38. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
39. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
40. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
Betarbet R; Poisik O; Sherer TB; Greenamyre JT
Exp Neurol; 2004 May; 187(1):76-85. PubMed ID: 15081590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
